Design and Synthesis of Novel Pyrazolopyrimidine Candidates As Promising EGFR-T790M Inhibitors and Apoptosis Inducers

References

• Curado MP , VotiL , Sortino-RachouAM. Cancer registration data and quality indicators in low and middle income countries: their interpretation and potential use for the improvement of cancer care. Cancer Causes Control20(5), 751–756 (2009).
   PubMed Web of Science ®Google Scholar
• Elshal M , EidN , El-SayedI , El-SayedW , Al-KarmalawyAA. Concanavalin-A shows synergistic cytotoxicity with tamoxifen via inducing apoptosis in estrogen receptor-positive breast cancer: in vitro and molecular docking studies. Pharm. Sci.28(1), 76–85 (2021).
   Google Scholar
• Son S , ElkamhawyA , GulARet al. Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines. J. Enzyme Inhib. Med. Chem.38(1), 2202358 (2023).
   PubMed Web of Science ®Google Scholar
• Torre LA , BrayF , SiegelRL , FerlayJ , Lortet-TieulentJ , JemalA. Global cancer statistics, 2012. CA Cancer J. Clin.65(2), 87–108 (2015).
   PubMed Web of Science ®Google Scholar
• Martínez-Jiménez F , MuiñosF , SentísIet al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer20(10), 555–572 (2020).
   PubMed Web of Science ®Google Scholar
• Demaria M , O'LearyMN , ChangJet al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov.7(2), 165–176 (2017).
   PubMed Web of Science ®Google Scholar
• Al-Karmalawy AA , NafieMS , ShaldamMAet al. Ligand-based design on the dog-bone-shaped BIBR1532 pharmacophoric features and synthesis of novel analogues as promising telomerase inhibitors with in vitro and in vivo evaluations. J. Med. Chem.66(1), 777–792 (2023).
   PubMed Web of Science ®Google Scholar
• El-Kalyoubi S , KhalifaMM , Abo-ElfadlMTet al. Design and synthesis of new spirooxindole candidates and their selenium nanoparticles as potential dual topo I/II inhibitors, DNA intercalators, and apoptotic inducers. J. Enzyme Inhib. Med. Chem.38(1), 2242714 (2023).
   PubMed Web of Science ®Google Scholar
• Chang J , RenH , ZhaoMet al. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro. Eur. J. Med. Chem.138, 669–688 (2017).
   PubMed Web of Science ®Google Scholar
• Gaber AA , El-MorsyAM , SherbinyFFet al. Pharmacophore-linked pyrazolo[3,4-d]pyrimidines as EGFR-TK inhibitors: synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies. Arch. Pharm. (Weinheim)31, e2100258 (2021).
   Google Scholar
• Khattab M , Al-KarmalawyAA. Computational repurposing of benzimidazole anthelmintic drugs as potential colchicine binding site inhibitors. Future Med. Chem.13(19), 1623–1638 (2021).
   PubMed Web of Science ®Google Scholar
• Kasture VS , MusmadeDS , AherSJ , PatilPP. Tyrosine kinases: promising targets for cancer chemotherapy. Med. Chem. Drug Discov.2(2), 37–51 (2012).
   Google Scholar
• Al-Muntaser SM , Al-KarmalawyAA , El-NaggarAM , AliAK , AbdEl-Sattar NEA , AbbassEM. Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC Adv.13(18), 12184–12203 (2023).
   PubMed Web of Science ®Google Scholar
• Huang M , ShenA , DingJ , GengM. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol. Sci.35(1), 41–50 (2014).
   PubMed Web of Science ®Google Scholar
• Nasser AA , EissaIH , OunMRet al. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M. Org. Biomol. Chem.18(38), 7608–7634 (2020).
   PubMed Web of Science ®Google Scholar
• Chen Y , WuJ , WangAet al. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC. Eur. J. Med. Chem.139, 674–697 (2017).
   PubMed Web of Science ®Google Scholar
• Zaoui K , BossowS , GrossardtCet al. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Cancer Gene Ther.19(3), 181–191 (2012).
   PubMed Web of Science ®Google Scholar
• Elshaier YA , ShaabanMA , AbdEl Hamid MKet al. Design and synthesis of pyrazolo[3,4-d]pyrimidines: nitric oxide releasing compounds targeting hepatocellular carcinoma. Bioorg. Med. Chem.25(12), 2956–2970 (2017).
   PubMed Web of Science ®Google Scholar
• Gaber AA , BayoumiAH , El-MorsyAM , SherbinyFF , MehanyAB , EissaIH. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Bioorg. Chem.80, 375–395 (2018).
   PubMed Web of Science ®Google Scholar
• Al-Warhi T , Al-KarmalawyAA , ElmaatyAAet al. Biological evaluation, docking studies, and in silico ADME prediction of some pyrimidine and pyridine derivatives as potential EGFRWT and EGFRT790M inhibitors. J. Enzyme Inhib. Med. Chem.38(1), 176–191 (2023).
   PubMed Web of Science ®Google Scholar
• El-Naggar AM , HassanAMA , ElkaeedEB , AlesawyMS , Al-KarmalawyAA. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2. Bioorg. Chem.123, 105770 (2022).
   PubMed Web of Science ®Google Scholar
• Belal A , AbdelGawad NM , MehanyABMet al. Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1,4]diazepine derivatives as potent EGFR/CDK2 inhibitors. J. Enzyme Inhib. Med. Chem.37(1), 1884–1902 (2022).
   PubMedGoogle Scholar
• Gaber AA , SobhyM , TurkyAet al. Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M. J. Enzyme Inhib. Med. Chem.37(1), 2283–2303 (2022).
   PubMed Web of Science ®Google Scholar
• Saito H , FukuharaT , FuruyaNet al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol.20(5), 625–635 (2019).
   PubMed Web of Science ®Google Scholar
• Tanzadehpanah H , MahakiH , MoradiMet al. Human serum albumin binding and synergistic effects of gefitinib in combination with regorafenib on colorectal cancer cell lines. Colorectal Cancer7(2), CRC03 (2018).
   Web of Science ®Google Scholar
• Kim Y , LeeS-H , AhnJS , AhnM-J , ParkK , SunJ-M. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res. Treat.51(2), 502–509 (2019).
   PubMed Web of Science ®Google Scholar
• Afshar S , PashakiAS , NajafiRet al. Cross-resistance of acquired radioresistant colorectal cancer cell line to gefitinib and regorafenib. Iran. J. Med. Sci.45(1), 50 (2020).
   PubMed Web of Science ®Google Scholar
• Allam HA , AlyEE , FaroukAK , ElKerdawy AM , RashwanE , AbbassSE. Design and synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents. Bioorg. Chem.98, 103726 (2020).
   PubMed Web of Science ®Google Scholar
• Kobayashi S , BoggonTJ , DayaramTet al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.352(8), 786–792 (2005).
   PubMed Web of Science ®Google Scholar
• Ayati A , MoghimiS , SalarinejadS , SafaviM , PouramiriB , ForoumadiA. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg. Chem.99, 103811 (2020).
   PubMed Web of Science ®Google Scholar
• Kim Y , KoJ , CuiZet al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol. Cancer Ther.11(3), 784–791 (2012).
   PubMed Web of Science ®Google Scholar
• Dong H , YinH , ZhaoC , CaoJ , XuW , ZhangY. Design, synthesis and biological evaluation of novel osimertinib-based HDAC and EGFR dual inhibitors. Molecules24(13), 2407 (2019).
   PubMed Web of Science ®Google Scholar
• Sogabe S , KawakitaY , IgakiSet al. Structure-based approach for the discovery of pyrrolo[3,2-d]pyrimidine-based EGFR T790M/L858R mutant inhibitors. ACS Med. Chem. Lett.4(2), 201–205 (2013).
   PubMed Web of Science ®Google Scholar
• Hung C-J , LaiP-J , ChengJ-J , WeyS-J , HsiaoY-P , WuM-F. A case with psoriasis-like lesions induced by olmutinib (HM61713) while treating epidermal growth factor receptor T790M mutant advanced lung adenocarcinoma. Dermatol. Sin.37(3), 154 (2019).
   Web of Science ®Google Scholar
• Brentnall M , Rodriguez-MenocalL , DeGuevara RL , CeperoE , BoiseLH. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol.14(1), 1–9 (2013).
   PubMedGoogle Scholar
• Bourguet CB , BoulayP-L , ClaingA , LubellWD. Design and synthesis of novel azapeptide activators of apoptosis mediated by caspase-9 in cancer cells. Bioorg. Med. Chem. Lett.24(15), 3361–3365 (2014).
   PubMed Web of Science ®Google Scholar
• Ozaki T , NakagawaraA. Role of p53 in cell death and human cancers. Cancers (Basel)3(1), 994–1013 (2011).
   PubMedGoogle Scholar
• Al-Karmalawy AA , RashedM , SharakyMet al. Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: design, synthesis, and biological assessments. Eur. J. Med. Chem.259, 115661 (2023).
   PubMed Web of Science ®Google Scholar
• Kumar S , DeepA , NarasimhanB. A review on synthesis, anticancer and antiviral potentials of pyrimidine derivatives. Curr. Bioact. Compd15(3), 289–303 (2019).
   Google Scholar
• Abdellatif KR , BakrRB. Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment. Med. Chem. Res.30(1), 31–49 (2021).
   Web of Science ®Google Scholar
• Xiao Z , ChuC , ZhouLet al. Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors. Bioorg. Med. Chem.28(19), 115669 (2020).
   PubMed Web of Science ®Google Scholar
• Xiao Z , ZhouZ , ChuCet al. Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations. Eur. J. Med. Chem.203, 112511 (2020).
   PubMed Web of Science ®Google Scholar
• Kassab AE . Pyrazolo[3,4-d]pyrimidine scaffold: a review on synthetic approaches and EGFR and VEGFR inhibitory activities. Arch. Pharm. (Weinheim)356(1), e2200424 (2023).
   PubMed Web of Science ®Google Scholar
• Gaber AA , SobhyM , TurkyAet al. Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M. J. Enzyme Inhib. Med. Chem.37(1), 2283–2303 (2022).
   PubMed Web of Science ®Google Scholar
• Bahmani A , TanzadehpanahH , MoghadamNH , SaidijamM. Introducing a pyrazolopyrimidine as a multi-tyrosine kinase inhibitor, using multi-QSAR and docking methods. Mol. Divers.25, 949–965 (2021).
   PubMed Web of Science ®Google Scholar
• Skehan P , StorengR , ScudieroDet al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl Cancer Inst.82(13), 1107–1112 (1990).
   PubMed Web of Science ®Google Scholar
• El-Kalyoubi S , ElbaramawiSS , EissaAGet al. Design and synthesis of novel uracil-linked Schiff bases as dual histone deacetylase type II/topoisomerase type I inhibitors with apoptotic potential. Future Med. Chem.15(11), 937–958 (2023).
   PubMed Web of Science ®Google Scholar
• El-Behairy MF , Abd-AllahWH , KhalifaMMet al. Design and synthesis of novel rigid dibenzo[b,f]azepines through ring closure technique as promising anticancer candidates against leukaemia and acting as selective topoisomerase II inhibitors and DNA intercalators. J. Enzyme Inhib. Med. Chem.38(1), 2157825 (2023).
   PubMed Web of Science ®Google Scholar
• Mouffouk C , MouffoukS , MouffoukS , HambabaL , HabaH. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2). Eur. J. Pharmacol.891, 173759 (2021).
   PubMed Web of Science ®Google Scholar
• Mourad MAE , AboElmaaty A , ZakiIet al. Novel topoisomerase II/EGFR dual inhibitors: design, synthesis and docking studies of naphtho[2′,3′:4,5]thiazolo[3,2-a]pyrimidine hybrids as potential anticancer agents with apoptosis inducing activity. J. Enzyme Inhib. Med. Chem.38(1), 2205043 (2023).
   PubMed Web of Science ®Google Scholar
• Al-Karmalawy AA , AlnajjarR , ElmaatyAAet al. Investigating the promising SARS-CoV-2 main protease inhibitory activity of secoiridoids isolated from Jasminum humile; in silico and in vitro assessments with structure–activity relationship. J. Biomol. Struct. Dyn. doi: 10.1080/07391102.2023.2240419 (2023) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Taher RF , Al-KarmalawyAA , AbdEl Maksoud AIet al. Two new flavonoids and anticancer activity of Hymenosporum flavum: in vitro and molecular docking studies. J. Herbmed Pharmacol.10(4), 443–458 (2021).
   Google Scholar
• Elagawany M , ElmaatyAA , MostafaAet al. Ligand-based design, synthesis, computational insights, and in vitro studies of novel N-(5-nitrothiazol-2-yl)-carboxamido derivatives as potent inhibitors of SARS-CoV-2 main protease. J. Enzyme Inhib. Med. Chem.37(1), 2112–2132 (2022).
   PubMed Web of Science ®Google Scholar
• Elebeedy D , BadawyI , ElmaatyAAet al. In vitro and computational insights revealing the potential inhibitory effect of tanshinone IIA against influenza A virus. Comput. Biol. Med.141, 105149 (2022).
   PubMed Web of Science ®Google Scholar
• Khalifa MM , Al-KarmalawyAA , ElkaeedEBet al. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J. Enzyme Inhib. Med. Chem.37(1), 299–314 (2022).
   PubMed Web of Science ®Google Scholar
• Ezz Eldin RR , SalehMA , AlotaibiMHet al. Ligand-based design and synthesis of N‘-benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by in vitro, in vivo, and in silico approaches with SAR studies. J. Enzyme Inhib. Med. Chem.37(1), 1098–1119 (2022).
   PubMed Web of Science ®Google Scholar
• Madbouly E , LashineE-S , Al-KarmalawyAAet al. Design and synthesis of novel quinazolinone–chalcone hybrids as potential apoptotic candidates targeting caspase-3 and PARP-1: in vitro, molecular docking, and SAR studies. New J. Chem.46, 22013–22029 (2022).
   Web of Science ®Google Scholar
• Gaber AA , El-MorsyAM , SherbinyFFet al. Pharmacophore-linked pyrazolo[3,4-d]pyrimidines as EGFR-TK inhibitors: synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies. Arch. Pharm. (Weinheim)31, e2100258 (2021).
   Google Scholar
• To C , BeyettTS , JangJet al. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat. Cancer3(4), 402–417 (2022).
   PubMedGoogle Scholar